- Home
- EQH vs BIIB Comparison
EQH vs BIIB Comparison
Compare EQH & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQH
- BIIB
- Stock Information
- Founded
- EQH 1859
- BIIB 1978
- Country
- EQH United States
- BIIB United States
- Employees
- EQH N/A
- BIIB N/A
- Industry
- EQH Specialty Insurers
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- EQH Finance
- BIIB Health Care
- Exchange
- EQH Nasdaq
- BIIB Nasdaq
- Market Cap
- EQH 16.2B
- BIIB 18.7B
- IPO Year
- EQH N/A
- BIIB 1991
- Fundamental
- Price
- EQH $45.74
- BIIB $160.85
- Analyst Decision
- EQH Buy
- BIIB Buy
- Analyst Count
- EQH 11
- BIIB 24
- Target Price
- EQH $64.18
- BIIB $174.62
- AVG Volume (30 Days)
- EQH 2.8M
- BIIB 1.6M
- Earning Date
- EQH 11-04-2025
- BIIB 10-30-2025
- Dividend Yield
- EQH 2.37%
- BIIB N/A
- EPS Growth
- EQH N/A
- BIIB N/A
- EPS
- EQH N/A
- BIIB 10.97
- Revenue
- EQH $12,224,000,000.00
- BIIB $10,065,900,000.00
- Revenue This Year
- EQH $17.79
- BIIB $2.97
- Revenue Next Year
- EQH $3.00
- BIIB N/A
- P/E Ratio
- EQH N/A
- BIIB $14.72
- Revenue Growth
- EQH 13.38
- BIIB 4.77
- 52 Week Low
- EQH $41.39
- BIIB $110.04
- 52 Week High
- EQH $56.61
- BIIB $175.86
- Technical
- Relative Strength Index (RSI)
- EQH 38.31
- BIIB 68.50
- Support Level
- EQH $44.35
- BIIB $151.83
- Resistance Level
- EQH $45.53
- BIIB $157.79
- Average True Range (ATR)
- EQH 1.26
- BIIB 5.10
- MACD
- EQH -0.19
- BIIB 0.86
- Stochastic Oscillator
- EQH 27.94
- BIIB 94.34
About EQH Equitable Holdings Inc.
Equitable Holdings Inc is a financial services company in the U.S. The company provides variable annuities, tax-deferred investment and retirement plans, employee benefits, and protection solutions for individuals, families, and small businesses. Its business segments include Individual Retirement, Group Retirement, Asset Management, Protection Solutions, Wealth Management, and Legacy. It generates the majority of its revenue from the Asset Management segment which provides diversified investment management and related solutions globally to a broad range of clients through three main client channels - Institutional, Retail, and Private Wealth.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.